Laboratory Services News & Publications
Important Testing Notification
Please see important testing notification regarding potential for false-positive Norovirus with Gastrointestinal Infection Array (GIIA) Testing.
Testing Updates
May 27, 2025
Important Test Announcement: Phenylalanine/Tyrosine, Plasma and Phenylalanine/Tyrosine, Dried Blood Spot & Maple Syrup Urine Disease (MSUD) Monitor, Dried Blood Spot
April 8, 2025
April 1, 2025
Important Test Announcement: Stat Peripheral Blood, Chromosome Analysis Test Name Update & Bone Marrow Transplant Cytogenetic and Molecular Genetic Testing Updates
March 25, 2025
Important Test Announcement: New Antimicrobial Susceptibility Panels for Enteric Gram-Negative Rods
March 11, 2025
Important Test Announcement: TSH with Reflex to Free T4
March 10, 2025
Important Test Announcement: Discontinuation of Stool Rotavirus Antigen
March 4, 2025
Important Test Announcement: Updates To HLH Cytokine Urgent Panel and HLH Cytokine Routine Panel
February 25, 2025
Important Test Announcement: Von Willebrand Factor Glycoprotein 1b-Binding Activity
February 19, 2025
Important Test Announcement: Urine Protein Tests Update 2/19/2025
January 29, 2025
Important Test Announcement: Urine Protein Tests Update
January 15, 2025
Important Test Announcement: Somatic Disease/Germline Comparator Exome
January 10, 2025
Important Test Announcement: DNA Ploidy
January 7, 2025
New Test Announcement: Adeno-Associated Virus 9 Antibody
January 2, 2025
Important Test Update: Inactivation of Whole Exome Sequencing Reanalysis
December 17, 2024
New Test announcement: Pentobarbital
December 16
New Test Announcement CXCL9 Quantitation, Serum
Important Test Announcement: Institute for Genomic Medicine (IGM) Additional Acceptable Sample Types
December 10, 2024
Important Test Announcement: Temporary Sendout of Peripheral Blood Chromosome Analysis
December 3, 2024
Important Test Announcement: Urine Catecholamine Fractionation, Free
October 30, 2024
Important Specimen Collection Product Announcement: Cary Blair Stool Transport Vial Temporary Substitution
October 14, 2024
Important Test Announcement- Eculizumab and sC5B-9 Complement
September 10, 2024
Important Test Announcement: Functional assessment of canonical NFkB pathway and TLR4 (FINNPN) and Functional innate immune panel for inflammasome and canonical NFkB pathways (FINNPC)
September 9, 2024
Important Test Announcement- Updated Policy on Extracted RNA Specimens for Hematologic Cancer Fusion Analysis
September 3, 2024
Important Test Announcement:Candida species Amphotericin B susceptibility testing to be discontinued
August 20, 2024
New Test Announcement: Granulocyte Oxidative Burst Panel
July 31, 2024
Important Test Announcement: SNP Microarray Test Update
July 8, 2024
Important Test Announcement: Discontinuation of Whole Exome Sequencing (Patient Samples) and NGS Rasopathy Panel
June 25, 2024
New Test Announcement: Fetal Urine Testing
June 19, 2024
Important Test Announcement: Positive Clostridium difficile Reflex to Toxin Assay
June 18, 2024
New Test Announcement: Hepatitis A Virus Antibodies, Total
June 17, 2024
Important Test Announcement: Chlamydia trachomatis and Neisseria gonorrhoeae Collection Update
June 10, 2024
New Tests Announcement:
May 20, 2024
Important Test Announcement: Trypanosome cruzi Antibody Total, Reflex to Confirmation
New Reference Ranges
October 15, 2024-
Changes in reference range for Quantitative Factor XIII
May 14, 2024
Changes in reference range for Microscopic Urinalysis
Laboratory Services Newsletters
2025 Newsletters
2024 Newsletters
Sexually Transmitted Infection Testing Resources
Nationwide Children’s Laboratory Services provides resources for health care professionals, including a Sexually Transmitted Infections Practice Tool. Visit Clinical Tools for a complete list.
Included in the current STI Practice Tool are recommendations from the Centers for Disease Control and Prevention (CDC) regarding “opt-out” testing policies.
According to CDC recommendations, providers might consider opt-out chlamydia and gonorrhea screening (i.e., the patient is notified that testing will be performed unless the patient declines, regardless of reported sexual activity) for adolescent and young adult females during clinical encounters. Cost-effectiveness analyses indicate that opt-out chlamydia screening among adolescent and young adult females might substantially increase screening, be cost saving and identify infections among patients who do not disclose sexual behavior.
Nationwide Children’s has provided sample opt-out letters that providers may download and customize for patient/parent communication:
Patient Letter (Customizable)
Download:
Parent Letter (Customizable)
Download: